Core Viewpoint - Roche showcases its comprehensive blood product portfolio at the 8th China International Import Expo, emphasizing its commitment to advancing the treatment of blood diseases and contributing to the "Healthy China 2030" initiative [1] Group 1: Innovations in Blood Disease Treatment - Roche has introduced four innovative blood cancer drugs in the last four years, covering a wide range of indications for aggressive and indolent lymphomas, marking a significant expansion in its treatment offerings [2] - The company has actively participated in the establishment of a multi-tiered medical insurance system in China, with its drug MabThera being one of the first original drugs included in the national medical insurance list [2] Group 2: New Drug Developments and Approvals - The company is set to showcase new indications for its foundational drug for indolent lymphoma, Ocrevus, which may soon be approved for treating lupus nephritis [3] - Roche's innovative treatment for hemophilia, NXT007, aims to achieve "zero bleeding" for patients with type A hemophilia, demonstrating its commitment to advancing non-factor preventive therapies [3] Group 3: Strategic Partnerships and Ecosystem Development - Roche aims to enhance the ecological construction of the blood cancer field in China, expanding its focus from lymphoma to multiple myeloma [3] - The company emphasizes its dedication to improving patient accessibility and affordability in China, while also enhancing the international influence of Chinese research [3]

Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annua ...

Core Insights - Roche reported a total sales of 45.9 billion Swiss francs for the first nine months of 2025, representing a year-on-year growth of 7% [1] - The pharmaceutical division generated sales of 35.6 billion Swiss francs, up 9% year-on-year, while the diagnostics division achieved sales of 10.3 billion Swiss francs, with a growth of 1% [1] - Based on the performance in the first nine months, Roche raised its full-year guidance for 2025, projecting sales growth in the mid-single digits (CER) and Core EPS growth in the high single digits to low double digits [1] Product Development - Roche plans to decide or initiate Phase III clinical trials for ten new molecules this year [1] - The HER2 TKI is set to enter Phase III for HER2+ breast cancer, while Cevostamab has already entered Phase III for relapsed/refractory multiple myeloma (R/R MM) [1]